Achilles Therapeutics plc has established a research collaboration with Arcturus Therapeutics Holdings Inc. to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines targeting clonal neoantigens.
Spybiotech Ltd. has entered into a sponsored research agreement with the University of Oxford for the development of a vaccine against Epstein-Barr virus (EBV).
Evergreen Theragnostics Inc. has entered into a collaboration and licensing agreement with the Medical University of Innsbruck (MUI) to advance the development of novel radiopharmaceuticals.
Totus Medicines Inc. has entered into a multi-target research collaboration with Eli Lilly & Co. to discover small-molecule drug candidates against undisclosed targets in different therapeutic areas.
Lift Biosciences Ltd. has been awarded a grant of over £1 million (US$1.3 million) from Innovate UK that will fund a collaboration between Lift and researchers at the University of Cambridge.
A collaboration between Plaquetec Ltd. and a lab at the Babraham Institute has demonstrated the druggability of a pro-inflammatory protein discovered by Plaquetec.
Centogene NV and Evotec SE have announced the discovery of a new small molecule with potential to treat patients with type 2 and type 3 Gaucher disease, or neuronopathic Gaucher disease.
Fogpharma Inc. and Artbio Inc. have established a collaboration to co-develop a new class of α-radioligand therapeutics to maximize efficacy for patients with multiple types of cancer.
Neosphere Biotechnologies GmbH has entered into a collaboration with Kymera Therapeutics Inc. that seeks to unlock undrugged or poorly drugged disease-causing protein targets that can be addressed by targeted protein degradation.
RSS
